CMB-200

N/A

Report date: 2023/02/17 21:06:10

Base Information

Drug NameCMB-200
Drug Alias NameMesenchymal stem cell-based therapyAntimunocelCMB-200STaRT-41
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCommence Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCommence Bio Inc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A